Navigation Links
BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
Date:11/15/2007

BRUSSELS, Belgium and BRISBANE, Calif., Nov. 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced it has initiated a Phase 2 study of its lead PARP inhibitor, BSI-201, in patients with triple-negative breast cancer that do not express the estrogen, progesterone or HER2 receptors.

The company designed the Phase 2 trial in this indication-which represents a major unmet medical need-based on molecular biomarker data presented today showing that breast tumors that are estrogen-negative and progesterone- negative were more likely to overexpress PARP, as were HER2-negative tumors. The data were presented at European Organization for Research and Treatment of Cancer-National Cancer Institute-American Society for Clinical Oncology Annual Meeting on "Molecular Markers in Cancer" in Brussels.

"Our research shows clearly that not only is PARP overexpressed in breast tumors generally, it is even more likely to be overexpressed in triple- negative tumors. That suggests that PARP inhibition may be a particularly effective way to target those hard-to-treat cancers," said BiPar Executive Vice President Barry Sherman, M.D. "Our Phase 2 trial of BSI-201 will build on those insights and, if successful, will serve as powerful proof of our strategy to use molecular biomarker data to focus our clinical studies of BiPar's PARP inhibitors on tumors that markedly upregulate PARP."

Patients with triple-negative breast cancer, who make up 10 to 15 percent of all patients, have few effective therapeutic options. Neither targeted therapies such as Herceptin and Tykerb nor anti-estrogens such as tamoxifen provide a benefit, and triple-negative tumors are associated with a high rate of relapse. Such cancers are particularly prevalent in premenopausal African- American women.

"We are very excited about being able to offer patients with triple- negative metastatic breast cancer treatment
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
5. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
6. Enrollment Begins on Human PK Study for Medidur(TM) FA
7. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
11. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... RIDGE, N.J. , Oct. 22, 2014 /PRNewswire/ ... (RMANJ), a world-renowned leader in the field of ... rapid approach to embryonic screening. The research abstract, ... Society for Reproductive Medicine (ASRM) meeting in ... screening (CCS) and single gene defect (SGD) pre-implantation ...
(Date:10/22/2014)... ATLANTA , Oct. 22, 2014  CryoLife, Inc. ... and tissue processing company focused on cardiac and vascular ... , President and Chief Executive Officer, has been elected ... 2014. Steven G. Anderson , Executive ... Pat has proven to be an excellent leader who ...
(Date:10/22/2014)... Calif., Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... Second quarter overview: , Revenues of $53.9 ... , Diluted EPS of $0.24, up 33% over last ... Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... , PHOENIX , Feb. ... selected SCAN Health Plan Arizona as their Medicare Advantage Plan (MAPD) ... to join SCAN until March 31, 2010 . , ... is affiliated with more than 6,800 physician locations as well as ...
... , SAN DIEGO , Feb. 9 ... manufacturer of precision intravascular therapy guidance tools designed to enhance ... announced today that it has received 510(k) clearance from the ... Eye® Platinum digital IVUS catheter in the United States ...
Cached Medicine Technology:SCAN Health Plan Arizona Exceeds Expectations as Local Seniors Select Medicare Advantage Coverage 2SCAN Health Plan Arizona Exceeds Expectations as Local Seniors Select Medicare Advantage Coverage 3Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 2Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 3Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 4
(Date:10/25/2014)... Homeowners that are wondering how they can ... no more. Clean Crawls gives 5 signs of ... when it comes to insulation in their recently released ... by Clean Crawls, can cause problems throughout your entire ... has deteriorated, become damp, or been infested with pests ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... cold sores -- herpes simplex -- might increase the risk ... In fact, being a carrier of certain antibodies to the ... found. "The identification of a treatable cause [herpes ... said lead researcher Dr. Hugo Lovheim, an associate professor in ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... increased risks for certain cancers, one might think that high-risk ... a new study suggests that, at least with colon cancer, ... genes doubled their risk of colon cancer were no more ... "It didn,t make any difference, not at all," said study ...
(Date:10/22/2014)... Medical Solutions , the nation’s ... announce that our co-founder and CFO, Scott Anderson, ... 100 for 2014. Anderson was also named to ... in the staffing industry,” in 2013.     , Under ... staffing company in the U.S., was named a ...
(Date:10/22/2014)... October 22, 2014 Shriners Hospitals for ... will change the current location of Shriners Hospitals for ... Limestone across from the University of Kentucky Albert B. ... ambulatory care center, owned and operated by Shriners Hospitals ... needs of children and their families well into the ...
Breaking Medicine News(10 mins):Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3
... has produced a safe and effective Anthrax vaccine from ... to tobacco plants could help avoid side effects of ... anthrax vaccine fermentation process. Daniell feels that an ... acre of tobacco plant, as the threat of anthrax ...
... has approved to extend by five years the Revised National ... ,The extension of the program from Oct 1, 2005 to ... ($255 million). Of this, Rs.2.82 billion would be required in ... Plan (2007-12). ,"The direct benefit would be the treatment ...
... the France-based International Agency for Research on Cancer (IARC) as ... one of the major causes of death worldwide.// ... for 2005-06 and 2006-07 at a total expenditure of $5.99 ... ,"By becoming a participating state, India can channelize and ...
... field and people now a days need to be aware ... exclusive information about //cosmetic surgery and the associated treatments is ... says this website will provide details about the risks and ... not offered in the National Health Services. But currently many ...
... London a research by Oxford was carried on at ... the number of kids admitted over the summer weekends ... damages due // to outdoor activities like inline skating ... the weekends of 2003-2005. The study included children aged ...
... have larger brains have better intellect, according to McMaster ... also said that there were differences between women and ... journal Brain also said, said that in women, verbal ... 36% of the verbal IQ score. ...
Cached Medicine News:Health News:Details of Cosmetic Surgery in a Special Website. 2
... Made with elastic fabric, these head ... you need to begin testing. Each Electro-Cap ... to the International 10-20 System. When you ... you are using with your head cap ...
... orbital implant was conceived by Arthur C. ... a comprehensive review of the literature on ... dating back to 1885 (Mules 1885). This ... the performance of contemporary implants, allowed Perry ...
... Evisceration. The new MEDPOR PLUS ... MEDPOR Spheres with a bioactive glass ... throughout the sphere structure, promotes more ... PLUS sphere., ,MEDPOR is a biocompatible ...
... The STAAR Collamer ICL and the TORIC ... Made of Collamer, STAARs proprietary collagen copolymer, ... the ciliary sulcus. This unique material contains ... excellent biocompatibility and superior optical capability. The ...
Medicine Products: